BCRX — BioCryst Pharmaceuticals, Inc. stock price, charts and financials
QT48BioCryst Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.50 | Insider Own | 2.64% | Shs Outstand | 254.16M | Perf Week | 6.90% |
| Market Cap | 2.21B | Forward P/E | 15.00 | EPS next Y | 0.58 | Insider Trans | -1.10% | Shs Float | 214.93M | Perf Month | -13.80% |
| Enterprise Value | 2.26B | PEG | - | EPS next Q | 0.10 | Inst Own | - | Short Float | 15.84% | Perf Quarter | -3.45% |
| Income | -385.00M | P/S | 2.35 | EPS this Y | -54.02% | Inst Trans | - | Short Ratio | 7.88 | Perf Half Y | -11.52% |
| Sales | 940.00M | P/B | - | EPS next Y | 125.05% | ROA | -68.96% | Short Interest | 34.05M | Perf YTD | 11.28% |
| Book/sh | -1.79 | P/C | 6.25 | EPS next 5Y | - | ROE | 101.55% | 52W High | 11.22 -22.64% | Perf Year | 12.73% |
| Cash/sh | 1.39 | P/FCF | 5.78 | EPS past 3/5Y | - | ROIC | -88.96% | 52W Low | 6.00 44.67% | Perf 3Y | 26.16% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 47.80% 117.44% | Gross Margin | 23.52% | Volatility | 3.55% 3.40% | Perf 5Y | -42.89% |
| Dividend TTM | - | EV/Sales | 2.40 | EPS Y/Y TTM | -248.84% | Oper. Margin | -33.29% | ATR (14) | 0.39 | Perf 10Y | 91.19% |
| Dividend Ex-Date | - | Quick Ratio | 2.29 | Sales Y/Y TTM | 108.43% | Profit Margin | -40.90% | RSI (14) | 41.81 | Recom | 2.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.32 | EPS Q/Q | - | SMA20 | -6.12% | Beta | 0.56 | Target Price | 19.00 |
| Payout | 0.00% | Debt/Eq | 2.18 | Sales Q/Q | 33.74% | SMA50 | -8.04% | Rel Volume | 2.76 | Prev Close | 8.70 |
| Employees | 435 | LT Debt/Eq | -3.67 | Earnings | Nov 02 | SMA200 | 0.47% | Avg Volume | 4.62M | Price | 8.68 |
| IPO Date | Mar 04, 1994 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 94.58% 19.08% | Net Debt/EBITDA | -0.84 | Volume | 12,746,293 | Change | -0.23% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-10-26 | Downgrade | RBC Capital | Outperform → Sector Perform | $14 → $11 |
| Jul-07-26 | Reiterated | RBC Capital | Outperform | $15 → $14 |
| Jun-30-26 | Reiterated | Jefferies | Buy | $15 → $17 |
| Jun-30-26 | Reiterated | Cantor Fitzgerald | Overweight | $21 → $29 |
| Nov-05-25 | Reiterated | JMP Securities | Market Outperform | $27 → $25 |
| Nov-04-25 | Reiterated | Barclays | Equal Weight | $7.00 → $9.00 |
| Oct-14-25 | Reiterated | RBC Capital | Outperform | $15 |
| Oct-14-25 | Reiterated | Jefferies | Buy | $14 → $15 |
| Oct-01-25 | Reiterated | Evercore ISI | Outperform | $16 → $8.00 |
| Aug-06-24 | Reiterated | Barclays | Equal Weight | $14 → $7.00 |
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral serine protease inhibitor designed to manage hereditary angioedema. BioCryst's development pipeline includes several promising candidates: BCX9930: An oral factor D inhibitor in Phase II clinical trials for complement-mediated diseases. BCX9250: An oral activin receptor-like kinase-2 inhibitor undergoing Phase I clinical evaluation for fibrodysplasia ossificans progressiva. Galidesivir: An RNA dependent-RNA polymerase inhibitor, also in Phase I, aimed at treating a range of RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company engages in strategic collaborations and in-license agreements with numerous partners. These include pharmaceutical entities like Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, Shionogi & Co., Ltd., Green Cross Corporation, and Mundipharma International Holdings Limited. Their alliances also extend to governmental and academic organizations such as the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services, The University of Alabama at Birmingham, Albert Einstein College of Medicine of Yeshiva University, and Industrial Research, Ltd. Established in 1986, BioCryst Pharmaceuticals, Inc. is headquartered in Durham, North Carolina.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 940 | 875 | 451 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 720 | 19 | 12 | — | — | — | — | — | — | |
| Gross Profit | 221 | 856 | 438 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 338 | 349 | 266 | — | — | — | — | — | — | |
| Research and Development | 197 | 166 | 175 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -314 | 341 | -3 | — | — | — | — | — | — | |
| Interest Expense | 76 | 79 | 99 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 5 | 14 | — | — | — | — | — | — | |
| Net Income Before Taxes | -382 | 267 | -87 | — | — | — | — | — | — | |
| Income Taxes | 3 | 4 | 2 | — | — | — | — | — | — | |
| Consolidated Net Income | -385 | 264 | -89 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -385 | 264 | -89 | — | — | — | — | — | — | |
| Net Income | -385 | 264 | -89 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.44 | 1.26 | -0.43 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.44 | 1.26 | -0.43 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.50 | 1.21 | -0.43 | — | — | — | — | — | — | |
| EBITDA | -303 | 348 | 13 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 6.45 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.35 | 1.87 | 3.45 | — | — | — | — | — | — | |
| Gross Margin | 23.51 | 97.83 | 97.12 | — | — | — | — | — | — | |
| Operating Margin | -33.40 | 38.97 | -0.67 | — | — | — | — | — | — | |
| Net Margin | -40.96 | 30.17 | -19.73 | — | — | — | — | — | — | |
| Shares Outstanding | 254 | 210 | 207 | — | — | — | — | — | — | |
| Market Capitalization | 2,205 | 1,638 | 1,557 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| McKee Amy E | Director | May 18 '26 | Sale | 8.97 | 11,180 | 100,285 | 31,252 | May 19 |
| Barnes Alane P | Chief Legal Officer | May 13 '26 | Option Exercise | 5.04 | 62,500 | 315,000 | 463,203 | May 15 |
| Barnes Alane P | Chief Legal Officer | May 13 '26 | Sale | 9.54 | 62,500 | 596,250 | 400,703 | May 15 |
| HEGGIE THERESA | Director | Mar 20 '26 | Option Exercise | 6.30 | 49,933 | 314,578 | 115,285 | Mar 24 |
| HEGGIE THERESA | Director | Mar 20 '26 | Sale | 10.11 | 49,933 | 504,823 | 65,352 | Mar 24 |
| Barnes Alane P | Chief Legal Officer | Mar 16 '26 | Option Exercise | 5.51 | 150,000 | 826,500 | 550,703 | Mar 18 |
| Barnes Alane P | Chief Legal Officer | Mar 16 '26 | Sale | 9.15 | 150,000 | 1,372,500 | 400,703 | Mar 18 |
| Stonehouse Jon P | Director | Mar 02 '26 | Option Exercise | 3.22 | 305,995 | 985,304 | 1,629,845 | Mar 03 |
| Gayer Charles K | President and CCO | Dec 22 '25 | Option Exercise | 5.01 | 74,233 | 371,896 | 952,583 | Dec 23 |
| Barnes Alane P | Chief Legal Officer | Dec 22 '25 | Sale | 7.65 | 21,773 | 166,563 | 398,751 | Dec 23 |
| Barnes Alane P | Chief Legal Officer | Dec 15 '25 | Sale | 7.65 | 21,210 | 162,257 | 315,726 | Dec 16 |
| Barnes Alane P | Chief Legal Officer | Dec 03 '25 | Sale | 7.65 | 19,770 | 151,241 | 345,476 | Dec 03 |
| Barnes Alane P | Chief Legal Officer | Dec 02 '25 | Sale | 7.21 | 50,906 | 367,216 | 365,246 | Dec 03 |
| Barnes Alane P | Chief Legal Officer | Dec 01 '25 | Sale | 7.10 | 91,004 | 646,511 | 416,152 | Dec 03 |
| Barnes Alane P | Chief Legal Officer | Dec 01 '25 | Option Exercise | 3.22 | 91,004 | 293,033 | 507,156 | Dec 03 |